drugset
drugset / Trial / NCT04391959

Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

NCT04391959 ↗

Phase 2 Completed 31 enrolled Azura Ophthalmics Avania · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

AZ202001 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD)

Timeline

Start
2020-07-17
Primary completion
2021-01-06
Completion
2021-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AZR-MD-001 Unknown — Other

Indications

eye adnexa disorder